{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:06:02Z","timestamp":1787018762322,"version":"build-2736575974"},"reference-count":61,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) is a long-term illness with no treatment options that address the disease directly. Solriamfetol is a selective dual norepinephrine-dopamine reuptake inhibitor that promotes wakefulness in obstructive sleep apnea and narcolepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study evaluated the efficacy and safety of solriamfetol for fatigue symptoms in adults with ME\/CFS over 8\u2009weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This was a phase 4, double-blind, randomized, placebo-controlled trial of solriamfetol in adults with ME\/CFS. Eligible participants (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u200938) were randomly assigned to receive 75\u2009mg (titrated to 150\u2009mg as needed) solriamfetol or placebo. Participants completed a battery of assessments at weekly visits. The primary outcome was Fatigue Symptom Inventory (FSI) scores, and the secondary outcome measure was Behavioral Rating Inventory of Executive Function for Adults (BRIEF-A), at Weeks 6 and 8. T-tests assessed the differences in mean change from baseline between solriamfetol and placebo. Adverse events were monitored throughout the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At Week 8 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.039), but not Week 6 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.270), solriamfetol improved FSI severity compared to placebo. On the BRIEF-A global executive composite, solriamfetol improved more than placebo at Week 8 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.012), driven by improved metacognition index (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004), but not behavioral regulation index (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.574). Solriamfetol was well tolerated, with most common AEs being sleep loss and headaches.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Solriamfetol demonstrated good safety and efficacy in improving fatigue and executive functioning in patients with ME\/CFS. As a dual norepinephrine-dopamine reuptake inhibitor and wakefulness-promoting factors, solriamfetol has the potential to improve fatigue symptoms of ME\/CFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number:<\/jats:title>\n                    <jats:p>NCT04622293<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251368371","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:02:50Z","timestamp":1758085370000},"page":"1268-1276","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis\/chronic fatigue syndrome after 8 weeks of treatment"],"prefix":"10.1177","volume":"39","author":[{"given":"Joel L.","family":"Young","sequence":"first","affiliation":[{"name":"Rochester Center for Behavioral Medicine, Rochester Hills, MI, USA"},{"name":"MedaData, LLC, Rochester Hills, MI, USA"},{"name":"School of Medicine - Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Powell","sequence":"additional","affiliation":[{"name":"MedaData, LLC, Rochester Hills, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Powell","sequence":"additional","affiliation":[{"name":"MedaData, LLC, Rochester Hills, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3555-5965","authenticated-orcid":false,"given":"Lisa L. M.","family":"Welling","sequence":"additional","affiliation":[{"name":"Department of Psychology, Oakland University, Rochester, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3497-7296","authenticated-orcid":false,"given":"Lauren","family":"Granata","sequence":"additional","affiliation":[{"name":"MedaData, LLC, Rochester Hills, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Saal","sequence":"additional","affiliation":[{"name":"Rochester Center for Behavioral Medicine, Rochester Hills, MI, USA"},{"name":"MedaData, LLC, Rochester Hills, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2014.12.003"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2007.00921.x"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2016.1200816"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.07.047"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2007.0089"},{"issue":"7","key":"e_1_3_3_7_1","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry 4(7): 28\u201337.","journal-title":"Psychiatry"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02428.x"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118796814"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13702"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics9030091"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.02.001"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.9.1249"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-83"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12102540"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1076\/chin.6.3.235.3152"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1076\/chin.8.4.249.13513"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00088"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.7.3.475"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70616"},{"key":"e_1_3_3_21_1","article-title":"US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs","author":"Guy W","year":"1976","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.","journal-title":"ECDEU assessment manual for psychopharmacology"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008900413113"},{"key":"e_1_3_3_23_1","unstructured":"Hann DM Jacobsen PB Azzarello LM et al. (1998) Measurement of fatigue in cancer patients: Development and validation of the Fatigue Symptom Inventory. Quality of Life Research 7(4): 301\u2013310. https:\/\/www.jstor.org\/stable\/4034523"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090139"},{"key":"e_1_3_3_25_1","unstructured":"Jazz Pharmaceuticals (2019) Sunosi: full prescribing information. Palo Alto CA. Available at: https:\/\/pp.jazzpharma.com\/pi\/sunosi.en.USPI.pdf (accessed 17 July 2025)."},{"key":"e_1_3_3_26_1","unstructured":"Kreijkamp-Kaspers S Brenu EW Marshall S et al. (2020) Treating chronic fatigue syndrome: A study into the scientific evidence for pharmacological treatments. Australian Family Physician 40(11): 907\u2013912. http:\/\/hdl.handle.net\/1854\/LU-1991684"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.2190\/T8EM-C8YH-373N-1UWD"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199310000-00005"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300873"},{"key":"e_1_3_3_30_1","unstructured":"Li D-Q Li Z-C Dai Z-Y (2015) Selective serotonin reuptake inhibitor combined with Dengzhanshengmai capsule improves the fatigue symptoms: A 12-week open-label pilot study. International Journal of Clinical and Experimental Medicine 8(7): 11811\u201311817. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4565405\/"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.08.003"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/NCM.0000000000000015"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.09.004"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140883"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-022-00488-1"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131045"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000026494"},{"key":"e_1_3_3_38_1","unstructured":"New York State Psychiatric Institute (2008) Columbia-Suicide Severity Rating Scale. The Research Foundation for Mental Hygiene Inc. Available at: https:\/\/www.cms.gov\/files\/document\/cssrs-screen-version-instrument.pdf (accessed 17 July 2025)"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00589"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.06.015"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-017-0674-5"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2024.03.044"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056531"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.02.011"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/09297049.2014.897318"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.5968"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50553"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1100OC"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f2b4d6"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2007.11.001"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0114"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25423"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/784520"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102433"},{"key":"e_1_3_3_55_1","unstructured":"United States: Health and Human Services Department: Office of Public Health and Science et al. (2014) Diagnosis and Treatment of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome. Health and Human Services Department. Available at: https:\/\/purl.fdlp.gov\/GPO\/gpo142110 (accessed 17 July 2025)"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-12-30"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202002-136OC"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20531"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0873-1"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2012.09.007"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4151"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11162322"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251368371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251368371","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251368371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:25Z","timestamp":1777507945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251368371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/02698811251368371"],"URL":"https:\/\/doi.org\/10.1177\/02698811251368371","relation":{"has-preprint":[{"id-type":"doi","id":"10.31234\/osf.io\/j6v5t_v1","asserted-by":"object"}]},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}